Linden Thomas Advisory Services’s Ligand Pharmaceuticals LGND Stock Holding History

Linden Thomas Advisory Services’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.14M	Sell	9,935 -6,734	-40%	-$1.59M	0.25%	117
2026 Q1	$3.33M	Buy	16,669 +94	+0.6%	+$18.6K	0.32%	86
2025 Q4	$3.13M	Sell	16,575 -231	-1%	-$44.4K	0.32%	85
2025 Q3	$2.98M	Buy	16,806 +14	+0.1%	+$2.08K	0.3%	86
2025 Q2	$1.91M	Sell	16,792 -167	-1%	-$17.9K	0.21%	152
2025 Q1	$1.78M	Sell	16,959 -49	-0.3%	-$5.54K	0.23%	149
2024 Q4	$1.82M	Sell	17,008 -20	-0.1%	-$2.26K	0.23%	148
2024 Q3	$1.7M	Sell	17,028 -84	-0.5%	-$8.46K	0.23%	162
2024 Q2	$1.44M	Buy	17,112 +271	+2%	+$21.6K	0.22%	187
2024 Q1	$1.23M	Buy	16,841 +448	+3%	+$33K	0.2%	219
2023 Q4	$1.17M	Sell	16,393 -386	-2%	-$22.8K	0.22%	200
2023 Q3	$1.01M	Sell	16,779 -29	-0.2%	-$1.91K	0.22%	200
2023 Q2	$1.21M	Buy	+16,808	New	+$1.26M	0.27%	149

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Linden Thomas Advisory Services's LGND Position: Q2 2026 in Review

Linden Thomas Advisory Services reduced its Ligand Pharmaceuticals (LGND) stake by 40% in Q2 2026, selling an estimated $1.59M and leaving 9,935 shares worth $3.14M. The position accounts for 0.25% of the portfolio, ranked #117.

Linden Thomas Advisory Services first reported a position in LGND in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.33M in Q1 2026. 416 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

Linden Thomas Advisory Services held 9,935 shares of Ligand Pharmaceuticals worth $3.14M as of Q2 2026.
Linden Thomas Advisory Services sold 6,734 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.59M.
Ligand Pharmaceuticals made up 0.25% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #117 holding.
Linden Thomas Advisory Services first reported a position in Ligand Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
Linden Thomas Advisory Services's Ligand Pharmaceuticals position peaked at $3.33M in Q1 2026.
416 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.